Jagsonpal Pharmaceuticals Ltd has acquired a 77.21% equity stake in Aequitas Healthcare Private Limited, increasing its holding from the previously reported 69.77%. This transaction confirms Aequitas Healthcare Private Limited as a subsidiary of the Jagsonpal Pharmaceuticals group, strengthening the company's market position.

The acquisition follows a proposal dated June 29, 2026, to purchase an 85% stake in the target entity. While the company has now secured 77.21% of the equity, the remaining portion of the proposed 85% stake is yet to be acquired. The disclosure was made to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Acquisition Details

The company completed the purchase of 77.21% of the equity stake out of the 85% proposed. Consequently, Aequitas Healthcare Private Limited has become a subsidiary company within the Jagsonpal Pharmaceuticals group. The remaining portion of the proposed 85% stake is yet to be acquired.

Transaction Summary

Jagsonpal Pharmaceuticals has disclosed that its promoters and promoter group members did not create any encumbrance over the company's shares during the financial year ended March 31, 2026. The declaration, submitted to BSE and NSE, confirms that no shares were encumbered directly or indirectly by the promoters, including Infinity Holdings, Rajpal Singh Kochhar, and Aresko Progressive Private Limited. This compliance filing was made under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Promoter Disclosures

The disclosure was signed by Pratham Rawal, Company Secretary & Compliance Officer of Jagsonpal Pharmaceuticals Limited, on April 09, 2026. Infinity Holdings, a promoter entity, separately declared via Director Ahmad Tariq Hossanee on April 06, 2026, that it had not made any encumbrance of shares during the specified period. Rajpal Singh Kochhar and Aresko Progressive Private Limited also confirmed the status based on information received from other promoter group members.

Shareholding Details

The filing includes an annexure listing the members of the promoter and promoter group. The table below details the shareholding for those entities where specific share counts were disclosed.

The list of promoter group members includes numerous entities such as Aresko Life Sciences Private Limited, Sewara Buildtech Private Limited, and various LLPs and trusts, though share counts were not specified for all entries in the annexure.